Indication
Biphasic Mesothelioma
1 clinical trial
1 drug
Clinical trial
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant MesotheliomaStatus: Active (not recruiting), Estimated PCD: 2026-03-20
Drug
mFOLFOX61 clinical trial
1 drug